Search filters
Filters
Clear All

Phase

  • 59
  • 97
  • 108
  • 89
  • 14
  • 170
  • 696
  • 449
  • 14
  • 31
  • 1
  • 4
  • 648

Found 698 none trials

A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Study to Evaluate the Safety and Feasibility of Exablate Model 4000 Type-2 to temporarily mediate Blood-Brain Barrier Disruption (BBBD) in patients with suspected infiltrating glioma in the setting of planned surgical interventions

A Study to Evaluate the Safety and Feasibility of Exablate Model 4000 Type-2 to temporarily mediate Blood-Brain Barrier Disruption (BBBD) in patients with suspected infiltrating glioma in the setting of planned surgical interventions

18 years - 99 years
All genders
The goal of this prospective, non-randomized, single-arm study is to evaluate the safety and feasibility of using ExAblate Model 4000 Type-2 Neuro-System as a tool to disrupt the blood brain barrier in a temporary and localized fashion in patients with suspected infiltrating glioma undergoing planned surgical interventions.
Learn More

UPCC 03621: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B (Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

99 years or below
All genders
TBD
Learn More

UPCC 04621: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02C (Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy

99 years or below
All genders
TBD
Learn More

Test SSO Now 5 PI123

C
Chace Brokaw Chace Brokaw
99 years or below
Female
Phase 1
Please see section 3 of the full protocol Please see section 3 of the full protocol Please see section 3 of the full protocol  PI123
Learn More
An Open Label Study to Assess the Safety and Efficacy of COR-003(2S 4R-Ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

An Open Label Study to Assess the Safety and Efficacy of COR-003(2S 4R-Ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

1 years - 99 years
All genders
Phase 3
The purpose of this clinical research study is to find out if the drug COR-003 is safe and has beneficial effects in patients who have Cushings disease and to determine the most effective dosage for each individual subject. . COR-003 is taken in pill form twice a day. The study …
Learn More
Zoster Eye Disease Study (ZEDS): A multi-center randomized double-masked placebo-controlled study of valacyclovir in immunocompetent subjects with a history of dendriform epithelial keratitis stromal keratitis endothelial keratitis and/or iritis due to Herpes Zoster Ophthalmicus (HZO) within the year prior to enrollment.

Zoster Eye Disease Study (ZEDS): A multi-center randomized double-masked placebo-controlled study of valacyclovir in immunocompetent subjects with a history of dendriform epithelial keratitis stromal keratitis endothelial keratitis and/or iritis due to Herpes Zoster Ophthalmicus (HZO) within the year prior to enrollment.

99 years or below
All genders
Phase 3
Request to rely on the lead site IRB, see attached documents
Learn More
Managed Access Program (MAP) to provide access to CTL019 for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

Managed Access Program (MAP) to provide access to CTL019 for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

99 years or below
All genders
The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who are unable to receive commercially manufactured product due to failure of the incoming apheresis material or outgoing product to meet the commercial specifications …
Learn More
A Phase III multi-center double-blind randomized withdrawal study of LCI699 following a 24 week single-arm open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushings disease (PRIME)

A Phase III multi-center double-blind randomized withdrawal study of LCI699 following a 24 week single-arm open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushings disease (PRIME)

1 years - 99 years
All genders
Phase 3
The study aims to confirm the long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's disease who have had had surgery that has not been successful, or are not a good surgical candidate, or refuse surgery, and have not received radiation treatment for this condition within …
Learn More
UPCC 35217: A Phase 1B/2 Open label study of Niraparib plus either Ipilimumab or Nivolumab in patients with advanced Pancreatic Cancer who have achieved stability on platinum- based therapy

UPCC 35217: A Phase 1B/2 Open label study of Niraparib plus either Ipilimumab or Nivolumab in patients with advanced Pancreatic Cancer who have achieved stability on platinum- based therapy

99 years or below
All genders
Phase 2
The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib with either ipilimumab or nivolumab on patients and their pancreatic cancer.
Learn More
EFICACIA Y SEGURIDAD DE UN MEDICAMENTO INYECTABLE UNA VEZ A LA SEMANA EN PARTICIPANTES CON SOBREPESO U OBESIDAD. (REDEFINIR 1)

EFICACIA Y SEGURIDAD DE UN MEDICAMENTO INYECTABLE UNA VEZ A LA SEMANA EN PARTICIPANTES CON SOBREPESO U OBESIDAD. (REDEFINIR 1)

1 years - 99 years
All genders
Phase 3
Este es un estudio de prueba de concepto multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 2 brazos, de grupos paralelos. El objetivo principal de este estudio es evaluar el efecto de dupilumab en el alivio de los síntomas clínicos de la EoE y la reducción de la inflamación esofágica …
Learn More
351 - 360 of 698